David J. Gilman
Imperial Chemical Industries
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by David J. Gilman.
Life Sciences | 1979
Tobias O. Yellin; Stephen H. Buck; David J. Gilman; Derrick Fleet Jones; J.Michael Wardleworth
In vitro, ICI 125,211 competitively antagonized the action of dimaprit on guinea pig atrium with an apparent dissociation constant of 1.5 × 10−8M (pA2 = 7.8). In vivo, the histamine dose-response curve in conscious gastric fistula beagles was shifted rightward in parallel without change in the maximal response by intravenous infusions of ICI 125,211 at doses of 0.01 and 0.03 umol/kg/hr (estimated pA2 = 7.3). Our data show that this new drug is at least 10x more potent than cimetidine as an inhibitor of gastric secretion in the dog. ICI 125,211, which is an orally effective antisecretory agent in man and devoid of antiandrogenic activity, is the most potent selective H2-blocker described to date.
Archive | 1978
David J. Gilman; James Michael Wardleworth; Tobias O. Yellin
Annals of the New York Academy of Sciences | 1988
F. Thomas Boyle; David J. Gilman; Michael Barry Gravestock; J.Michael Wardleworth
Archive | 1979
Tobias O. Yellin; David J. Gilman
Archive | 1979
Tobias O. Yellin; David J. Gilman
Archive | 1984
Tobias O. Yellin; David J. Gilman; Derrick Fleet Jones
Archive | 1982
Tobias O. Yellin; David J. Gilman
Archive | 1981
Tobias O. Yellin; David J. Gilman; Derrick Fleet Jones; Keith Oldham
Archive | 1985
Tobias O. Yellin; David J. Gilman
Archive | 1982
Tobias O. Yellin; David J. Gilman; Philip Neil Edwards; Michael Stewart Large; Derrick Fleet Jones; Keith Oldham